InsiderSignal.AI

InsiderSignal.ai

VRTX - Vertex Pharmaceuticals Inc / Ma

Insider Purchase by Kewalramani Reshma (CEO, Pres)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, Kewalramani Reshma, serving as CEO, Pres at Vertex Pharmaceuticals Inc / Ma (VRTX), purchased 10,000 shares at $389.58 per share, for a total transaction value of $3,895,768.00. Following this transaction, Kewalramani Reshma now holds 115,968 shares of VRTX.

This purchase represents a 9.00% increase in Kewalramani Reshma's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, August 6, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, August 7, 2025, 1 day after the trade was made.

Vertex Pharmaceuticals Inc / Ma operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Kewalramani Reshma

CEO, Pres

Reshma Kewalramani, M.D., FASN, is the Chief Executive Officer and President of Vertex Pharmaceuticals Incorporated (VRTX), a Fortune 500 global biotechnology company based in Boston, Massachusetts, a position she has held since April 1, 2020.[[1]](https://www.conference-board.org/bio/reshma-kewalramani)[[2]](https://en.wikipedia.org/wiki/Reshma_Kewalramani)[[5]](https://www.uml.edu/commencement/2025/distinguished-guests/reshma-kewalramani.aspx) She is the first female CEO of a large, public U.S. biotechnology company and currently the only woman leading a biopharma firm with over $100 billion market capitalization.[[2]](https://en.wikipedia.org/wiki/Reshma_Kewalramani)[[5]](https://www.uml.edu/commencement/2025/distinguished-guests/reshma-kewalramani.aspx) Under her leadership, Vertex has advanced cystic fibrosis treatments like Trikafta and Alyftrek, gained FDA approval for Casgevy—a CRISPR-based gene-editing therapy for sickle cell disease and beta thalassemia in collaboration with CRISPR Therapeutics—and progressed programs in type 1 diabetes, APOL1-mediated kidney disease, and pain.[[2]](https://en.wikipedia.org/wiki/Reshma_Kewalramani)[[3]](https://entrepreneurship.babson.edu/reshma-kewalramani-commencement/)[[5]](https://www.uml.edu/commencement/2025/distinguished-guests/reshma-kewalramani.aspx) The company has doubled its employee base, expanded its pipeline across modalities including small molecules, mRNA, cell, and gene therapies, and earned recognitions as a top workplace.[[1]](https://www.conference-board.org/bio/reshma-kewalramani)[[3]](https://entrepreneurship.babson.edu/reshma-kewalramani-commencement/) Dr. Kewalramani immigrated from India at age 11 and began her career as a physician at Massachusetts General Hospital, Brigham and Women's Hospital, Massachusetts Eye and Ear Infirmary, and MIT.[[2]](https://en.wikipedia.org/wiki/Reshma_Kewalramani)[[6]](https://time.com/collections/100-most-influential-people-2025/7273788/reshma-kewalramani/) She spent over 12 years at Amgen in research and development leadership roles, including Vice President of Global Clinical Development for Nephrology & Metabolic Therapeutic Area.[[4]](https://thebwwc.org/reshma-kewalramani-bio) Joining Vertex in 2017 as Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs, she trained in internal medicine and nephrology.[[1]](https://www.conference-board.org/bio/reshma-kewalramani)[[2]](https://en.wikipedia.org/wiki/Reshma_Kewalramani) Her achievements include rankings on Fortune's Most Powerful Women (2023) and TIME's 100 Most Influential People (2025).[[2]](https://en.wikipedia.org/wiki/Reshma_Kewalramani)[[6]](https://time.com/collections/100-most-influential-people-2025/7273788/reshma-kewalramani/)

View full insider profile →

Trade Price

$389.58

Quantity

10,000

Total Value

$3,895,768.00

Shares Owned

115,968

Trade Date

Wednesday, August 6, 2025

200 days ago

SEC Filing Date

Thursday, August 7, 2025

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Vertex Pharmaceuticals Inc / Ma

Company Overview

No company information available
View news mentioning VRTX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/111227

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime